

Cover Story
By Matthew Bin Han Ong
The House Committee on Energy and Commerce is spearheading legislation aimed streamlining development of drugs and medical devices.
By Matthew Bin Han Ong
In Brief


Trending Stories
- Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - In the Headlines: “There’s no one to stand up for NCI right now.”
- Bhattacharya cancels NIH all-hands meeting
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges